Cobamamide liposomal - HanAll BioPharma

Drug Profile

Cobamamide liposomal - HanAll BioPharma

Alternative Names: ADC liposomal gel; Adenosyl-B12 liposomal gel; Adenosylcobamide liposomal gel - HanAll BioPharma; Cobamide; HL-009; Liposomal adenosylcobalamin (vitamin B12) - HanAll Biopharma

Latest Information Update: 26 Jun 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator HanAll Biopharma; Korea Research Institute of Chemical Technology
  • Developer HanAll Biopharma
  • Class Vitamin B12 analogues
  • Mechanism of Action Nitric oxide inhibitors; Nitric oxide synthase inhibitors; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 26 Jun 2015 Phase II development is ongoing in the USA and South Korea
  • 01 Aug 2013 HanAll BioPharma completes a phase II trial in Atopic dermatitis in USA (NCT01568489)
  • 20 Apr 2012 HanAll BioPharma plans a phase III trial for Atopic dermatitis in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top